副作用

くすりの ふくさよう。

Medicine's side effect.

Basic noun phrase.

ふくさよう は ありますか？

Are there side effects?

Simple question structure.

あたま が いたい。 ふくさよう かな。

My head hurts. Maybe it's a side effect.

Simple sentence with 'kana' for speculation.

この くすり、ふくさよう が ない。

This medicine has no side effects.

Using 'ga nai' for negation.

ふくさよう に きをつけて。

Be careful of side effects.

Imperative form.

ねむい。 ふくさよう。

Sleepy. Side effect.

Simple statement of cause and effect.

ふくさよう が おおいです。

There are many side effects.

Using 'ooi' for 'many'.

これは ふくさよう ですか？

Is this a side effect?

Basic question with 'desu ka'.

この薬は、眠気という副作用があります。

This medicine has a side effect called drowsiness.

Using 'to iu' to specify the side effect.

薬をもらうとき、副作用について聞きました。

When I received the medicine, I asked about the side effects.

Using 'kiku' (to ask) and 'ni tsuite' (about).

軽い副作用なので、心配しないでください。

Because they are mild side effects, please do not worry.

Using 'karui' (mild) and 'na node' (because).

新しい治療法には、どんな副作用がありますか？

What kind of side effects does the new treatment method have?

Using 'donna' (what kind of) and 'arimasu ka'.

この薬の副作用で、気分が悪くなりました。

I felt sick due to the side effects of this medicine.

Using 'de' to indicate cause.

医師は副作用の説明を詳しくしてくれた。

The doctor explained the side effects in detail.

Using 'shite kureta' (did for me) and 'kuwashiku' (in detail).

健康食品にも、まれに副作用があるらしい。

It seems that health foods also rarely have side effects.

Using 'rashii' (it seems) and 'mare ni' (rarely).

その治療には、重い副作用のリスクがある。

There is a risk of serious side effects with that treatment.

Using 'omoi' (serious) and 'risuku ga aru' (there is a risk).

この新しい薬は、効果が高い一方で、いくつかの無視できない副作用も報告されています。

While this new medicine is highly effective, several non-negligible side effects have also been reported.

Using 'ippō de' (on the other hand) and 'mushi dekinai' (non-negligible).

処方箋を受け取る際に、薬剤師から副作用とその対処法について詳しい説明がありました。

When receiving the prescription, there was a detailed explanation from the pharmacist about the side effects and how to deal with them.

Using 'shohōsen' (prescription), 'yakuzaishi' (pharmacist), and 'taishohō' (countermeasures).

長期間の服用による副作用が懸念されるため、定期的な検査が必要です。

Because side effects from long-term medication are a concern, regular check-ups are necessary.

Using 'chōkikan no fukuyō' (long-term medication) and 'kenen sareru' (to be concerned).

広告では良い点ばかりが強調されがちですが、副作用についても理解しておくべきです。

Advertisements tend to emphasize only the good points, but one should also understand the side effects.

Using 'kyōchō sareru gachi' (tend to be emphasized) and 'rikai shite oku beki' (should understand).

アレルギー体質の方は、特に新しい薬の副作用に注意が必要です。

People with allergies need to be particularly careful of the side effects of new medicines.

Using 'arerugī taishitsu' (allergic constitution) and 'chūi ga hitsuyō' (caution is necessary).

この治療法は、まだ研究段階であり、未知の副作用が存在する可能性があります。

This treatment method is still in the research phase, and there is a possibility of unknown side effects existing.

Using 'kenkyū dankai' (research phase) and 'michi no' (unknown).

医師は、患者に副作用のリスクを正確に伝え、同意を得る責任がある。

The doctor has a responsibility to accurately convey the risks of side effects to the patient and obtain consent.

Using 'seikaku ni tsutaeru' (to convey accurately) and 'dōi o eru sekinin' (responsibility to obtain consent).

市販薬であっても、用法・用量を守らないと予期せぬ副作用を引き起こすことがある。

Even with over-the-counter drugs, not following the dosage and administration can cause unexpected side effects.

Using 'shihanyaku' (over-the-counter drug), 'yōhō yōryō' (dosage and administration), and 'yosugenu' (unexpected).

近年、医薬品の副作用に関する情報開示が強化されており、患者がより informed な意思決定を行えるようになっている。

In recent years, information disclosure regarding drug side effects has been strengthened, enabling patients to make more informed decisions.

Using 'jōhō kaiji' (information disclosure), 'kyōka sarete ori' (has been strengthened), and 'informed na ishi kettei' (informed decision-making).

特定の疾患に対する新薬の開発は、その有効性だけでなく、潜在的な副作用のプロファイルも綿密に評価される必要がある。

The development of new drugs for specific diseases requires not only their efficacy but also a thorough evaluation of their potential side effect profiles.

Using 'senzai na' (potential), 'purofairu' (profile), and 'menmitsu ni hyōka sareru' (to be meticulously evaluated).

慢性疾患の治療では、根本的な症状の改善と、副作用によるQOL（Quality of Life）の低下との間で、慎重なバランスが求められる。

In the treatment of chronic diseases, a careful balance is required between improving the fundamental symptoms and the decline in QOL (Quality of Life) due to side effects.

Using 'mansei shikkan' (chronic disease), 'konponteki na' (fundamental), and 'QOL no teika' (decline in QOL).

臨床試験において、プラセボ群と比較して有意な差が見られた副作用は、厳密に分析・報告される。

In clinical trials, side effects showing a significant difference compared to the placebo group are strictly analyzed and reported.

Using 'rinshō shiken' (clinical trial), 'purasebo gun' (placebo group), 'yūi na sa' (significant difference), and 'genmitsu ni bunseki' (strictly analyzed).

医療技術の進歩は目覚ましいが、それに伴う新たな副作用や倫理的な課題も無視できない。

Medical technology is advancing remarkably, but the new side effects and ethical issues that accompany it cannot be ignored.

Using 'mezamashii' (remarkable), 'tomonau' (accompany), and 'rinriteki na kadai' (ethical issues).

患者の病状や体質に応じて、副作用のリスクを最小限に抑えるための個別化された治療計画が重要となる。

Personalized treatment plans are important to minimize the risk of side effects, depending on the patient's condition and constitution.

Using 'byōjō' (condition), 'taishitsu' (constitution), 'saishōgen ni osaeru' (to minimize), and 'kobetsuka sareta' (personalized).

広範な文献調査の結果、特定の薬剤の副作用として、稀ながらも重篤な神経学的合併症が指摘されている。

As a result of extensive literature review, severe neurological complications, although rare, have been pointed out as side effects of a specific drug.

Using 'kōhan na bunken chōsa' (extensive literature review), 'jūtomu na' (severe), and 'shinkeigaku teki' (neurological).

予防接種後の副作用に関する国民の不安を解消するため、公的機関による正確な情報発信が不可欠である。

Accurate information dissemination by public institutions is essential to alleviate public anxiety regarding post-vaccination side effects.

Using 'yobō sesshu' (vaccination), 'kokumin no fuan' (public anxiety), 'kaishō suru tame' (to alleviate), and 'kōteki kikan' (public institution).

医薬品の承認プロセスにおいては、その治療効果と潜在的な副作用とのリスク・ベネフィット評価が厳格に行われる。

In the drug approval process, a risk-benefit assessment between its therapeutic effect and potential side effects is rigorously conducted.

Using 'shōnin purosesu' (approval process), 'chiryō kōka' (therapeutic effect), 'risuku-benefitto hyōka' (risk-benefit assessment), and 'genkaku ni okonawareru' (to be rigorously conducted).

薬理学的な観点から、特定の薬剤が引き起こす副作用の機序を解明することは、より安全な医薬品開発に不可欠である。

From a pharmacological perspective, elucidating the mechanism of side effects caused by specific drugs is essential for developing safer pharmaceuticals.

Using 'yakurigaku teki na kanten' (pharmacological perspective), 'kijo o kaimei suru' (to elucidate the mechanism), and 'anzen na iyakuhin kaihatsu' (development of safer pharmaceuticals).

近年、リアルワールドデータ（RWD）の活用により、これまで見過ごされがちだった稀な副作用の特定が可能になってきている。

In recent years, the utilization of Real-World Data (RWD) has made it possible to identify rare side effects that have often been overlooked.

Using 'riyō ni yori' (through utilization), 'misugosare gachi datta' (had been overlooked), and 'tokutei ga kanō ni natte kite iru' (has become possible to identify).

患者中心の医療においては、副作用に対する患者の懸念や許容度を十分に理解し、治療方針に反映させることが肝要である。

In patient-centered medical care, it is crucial to fully understand the patient's concerns and tolerance for side effects and reflect them in the treatment plan.

Using 'kanja chūshin no iryō' (patient-centered medical care), 'kenen' (concern), 'kyoyōdo' (tolerance), and 'kan'yō de aru' (it is crucial).

創薬プロセスにおける初期段階での副作用スクリーニングの精度向上は、開発コストの削減と上市までの期間短縮に寄与する。

Improving the accuracy of side effect screening in the early stages of the drug discovery process contributes to reducing development costs and shortening the time to market.

Using 'sōyaku purosesu' (drug discovery process), 'shoki dankai' (early stages), 'seido kōjō' (accuracy improvement), and 'jōshi made no kikan tanshuku' (shortening the time to market).

遺伝子治療や再生医療といった先端医療分野では、従来の医薬品とは異なる新たなタイプの副作用が出現する可能性があり、慎重なモニタリングが求められる。

In advanced medical fields such as gene therapy and regenerative medicine, there is a possibility of new types of side effects appearing that differ from conventional drugs, requiring careful monitoring.

Using 'sensen iryō bun'ya' (advanced medical fields), 'idenshi chiryō' (gene therapy), 'saisei iryō' (regenerative medicine), and 'shinchō na monitaringu' (careful monitoring).

薬物相互作用による予期せぬ副作用の発現を防ぐためには、患者が服用中の全ての薬剤情報を医療提供者に正確に伝えることが極めて重要である。

To prevent the occurrence of unexpected side effects due to drug interactions, it is extremely important for patients to accurately communicate all medication information they are currently taking to healthcare providers.

Using 'yakubutsu sōgo sayō' (drug interactions), 'hatsugen o fusegu tame ni' (to prevent the occurrence), and 'kyokume ni jūyō de aru' (it is extremely important).

長期間にわたる臨床研究は、特定の副作用の遅発性や累積効果を明らかにする上で、不可欠な役割を果たす。

Long-term clinical research plays an indispensable role in clarifying the delayed onset and cumulative effects of specific side effects.

Using 'chōkikan ni wataru' (over a long period), 'chiryo kenkyū' (clinical research), 'chihatsusei' (delayed onset), and 'ruiseki kōka' (cumulative effects).

医薬品の pharmacovigilance においては、市販後調査を通じて、予期せぬ副作用の早期発見とリスク評価の継続的な更新が求められる。

In pharmacovigilance of pharmaceuticals, early detection of unexpected side effects and continuous updating of risk assessment are required through post-marketing surveillance.

Using 'pharmacovigilance', 'shihango chōsa' (post-marketing surveillance), 'sōki hakken' (early detection), and 'keizoku teki na kōshin' (continuous updating).

個別化医療の進展に伴い、ゲノム情報に基づいた薬剤応答性予測と、それに起因する副作用のリスク低減戦略の統合が喫緊の課題となっている。

With the advancement of personalized medicine, the integration of drug response prediction based on genomic information and strategies to reduce the risk of resulting side effects has become an urgent issue.

Using 'komatsuka iryō no shinten' (advancement of personalized medicine), 'genomu jōhō ni motozuita' (based on genomic information), 'yakuzai ōtōsei yosoku' (drug response prediction), and 'kikkin no kadai' (urgent issue).

医薬品開発における非臨床試験段階での副作用予測モデルの構築は、動物実験の代替や倫理的配慮の観点からも極めて重要視されている。

The construction of side effect prediction models in the preclinical testing phase of drug development is considered extremely important from the perspectives of alternatives to animal testing and ethical considerations.

Using 'hi-rinshō shiken dankai' (preclinical testing phase), 'yosoku moderu no kōchiku' (construction of prediction models), 'daitai' (alternative), and 'rinriteki hairyo' (ethical considerations).

多剤併用療法における薬物相互作用は、予期せぬ副作用の発現リスクを増大させるだけでなく、治療効果の減弱を招く可能性も否定できない。

Drug interactions in polypharmacy not only increase the risk of unexpected side effects but also cannot deny the possibility of leading to a reduction in therapeutic efficacy.

Using 'tazai heiyō ryōhō' (polypharmacy), 'ryōhō kōka no genjaku' (reduction in therapeutic efficacy), and 'negai dekinai' (cannot deny).

医薬品の適正使用推進のためには、医療従事者への継続的な教育に加え、患者自身が副作用に関する知識を深めるための啓発活動が不可欠である。

To promote the appropriate use of pharmaceuticals, educational activities to deepen patients' own knowledge about side effects, in addition to continuous education for healthcare professionals, are indispensable.

Using 'tekisei shiyō suishin' (promotion of appropriate use), 'iryō jūjisha' (healthcare professionals), 'keihatsu katsudō' (awareness activities), and 'fukaketsu de aru' (is indispensable).

ナノテクノロジーを応用したドラッグデリバリーシステム（DDS）は、標的部位への薬剤送達効率を高める一方で、未知の副作用のリスク評価が新たな課題となっている。

Drug delivery systems (DDS) applying nanotechnology enhance the efficiency of drug delivery to target sites, but on the other hand, the risk assessment of unknown side effects has become a new challenge.

Using 'nanotekunorojī o ōyō shita' (applying nanotechnology), 'doraggu deribarii shisutemu' (drug delivery system), 'hyōteki bui' (target site), and 'atarashii kadai' (new challenge).

医薬品の安全性情報に関する国際的な調和が進む中で、各国の規制当局は副作用報告システムの標準化と、その共有メカニズムの構築を推進している。

Amidst the international harmonization of pharmaceutical safety information, regulatory authorities in each country are promoting the standardization of side effect reporting systems and the establishment of their sharing mechanisms.

Using 'anzensei jōhō ni kansuru' (concerning safety information), 'kokusaiteki na chōwa' (international harmonization), 'kisei tōkyoku' (regulatory authorities), and 'hyōjunka' (standardization).

精神科領域における長期処方薬の副作用、特に離脱症状や認知機能への影響については、未だ解明されていない側面が多く、継続的な研究が不可欠である。

Regarding the side effects of long-term prescribed drugs in the psychiatric field, especially withdrawal symptoms and effects on cognitive function, many aspects remain unclarified, making continuous research indispensable.

Using 'seishinka ryōiki' (psychiatric field), 'ridatsu shōjō' (withdrawal symptoms), 'ninchi kinō' (cognitive function), and 'imada kaimei sarete inai' (still unclarified).